Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Recruiting · NCT06572319 · Registry updated 2024-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens | HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2024-08-27 | NCT06572319 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhejiang Cancer Hospital | 142 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Zhejiang Cancer Hospital | Hangzhou | China | 164 |